Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines

Key Points Question What is the prevalence of germline findings in cancers lacking hereditary testing guidelines? Findings In this cross-sectional study including records from 34 642 patients, approximately 7% of patients with cancer harbored pathogenic or likely pathogenic germline variants. The prevalence of pathogenic or likely pathogenic germline findings was highest in bladder and lung cancers. Meaning The findings of this study suggest that paired tumor/normal sequencing has the potential added benefit of identifying germline findings, especially in cancer types, such as bladder and lung, in which germline testing may not be indicated without a suspicious family history of cancer.

[1]  N. Schultz,et al.  Therapeutic Implications of Germline Testing in Patients With Advanced Cancers , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Gelber,et al.  Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. , 2021, The New England journal of medicine.

[3]  David C. Smith,et al.  Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors , 2021, JAMA oncology.

[4]  R. Nussbaum,et al.  Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome. , 2020, JAMA oncology.

[5]  R. Nussbaum,et al.  Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer , 2020, JAMA network open.

[6]  Y. Drew,et al.  First-in-Human Trial of the Oral Ataxia Telangiectasia and Rad3-Related Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors. , 2020, Cancer discovery.

[7]  M. Mansukhani,et al.  Clinical Utilization, Utility, and Reimbursement for Expanded Genomic Panel Testing in Adult Oncology , 2020 .

[8]  N. Tunariu,et al.  Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  L. Siu,et al.  Molecular profiling for precision cancer therapies , 2020, Genome Medicine.

[10]  Kaanan P. Shah,et al.  Integrated genomic profiling expands clinical options for patients with cancer , 2019, Nature Biotechnology.

[11]  M. Dwyer,et al.  NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 3.2017. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[12]  J. Sicklick,et al.  Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study , 2019, Nature Medicine.

[13]  Kaanan P. Shah,et al.  Clinical validation of the tempus xT next-generation targeted oncology sequencing assay , 2019, Oncotarget.

[14]  Jubilee Brown,et al.  Patients with BRCA mutations have superior outcomes after intraperitoneal chemotherapy in optimally resected high grade ovarian cancer. , 2018, Gynecologic oncology.

[15]  Kaanan P. Shah,et al.  Clinical validation of the Tempus xO assay , 2018, Oncotarget.

[16]  P. Kantoff,et al.  Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing , 2017, JAMA.

[17]  Marie-Cécile Le Deley,et al.  High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. , 2017, Cancer discovery.

[18]  W. Chung,et al.  Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics , 2016, Genetics in Medicine.

[19]  Milan Radovich,et al.  Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers , 2016, Oncotarget.

[20]  Tao Wang,et al.  Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors. , 2016, JAMA oncology.

[21]  Ann M. Bailey,et al.  Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  Lisle E. Mose,et al.  Germline Analysis from Tumor–Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings , 2016, Clinical Cancer Research.

[23]  Donavan T. Cheng,et al.  Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. , 2016, JAMA oncology.

[24]  Li Ding,et al.  Germline Mutations in Predisposition Genes in Pediatric Cancer. , 2015, The New England journal of medicine.

[25]  Wei Yuan,et al.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. , 2015, The New England journal of medicine.

[26]  Nallasivam Palanisamy,et al.  Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. , 2015, JAMA.

[27]  Liang Zhao,et al.  FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy , 2015, Clinical Cancer Research.

[28]  Theresa Zhang,et al.  Personalized genomic analyses for cancer mutation discovery and interpretation , 2015, Science Translational Medicine.

[29]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[30]  Razelle Kurzrock,et al.  Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative , 2012, Clinical Cancer Research.

[31]  A. Knudson Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.